Key result
Antidepressants exert modulatory effects on severe medical disorders, while drugs such as statins and NSAIDs demonstrate favorable effects in depressive states.
This review highlights the bidirectional relationship between depression and systemic medical disorders, suggesting that targeting shared inflammatory and metabolic pathways could lead to personalized treatment strategies.
May inform comorbid depression and CVD management; leaves open need for RCTs to validate repurposing.
The depressive state has been characterised as one of elevated inflammation, changed cardiovascular parameters and a deranged metabolic situation all of which holds promise for a better understanding and handling of treatment-resistance in affective disorders as well as for future developments in treatment algorithms. In this context several biomarkers are differentially regulated by antidepressant treatment and connected to metabolic, inflammatory, cardiovascular and apoptotic components of the pathophysiology, i.e. adiponectin, apolipoprotein-B, B-type natriuretic peptide, cortisol, CRP, cysteine, homocysteine, fibrinogen, adiponectin, BMI, glycated hemoglobin A1c, leptin, interferon-gamma, high-density lipoprotein, interleukin interleukin-1alpha, -1beta, -2, -4, -5, -6, -8, -10, -12, -13, -17, insulin-like growth factor-1, low-density lipoprotein, myeloperoxidase, osteoprotegerin, tumour necrosis factor alpha, troponins, triglycerides etc. In this context antidepressants exert different modulatory effects on the outcome, incidence and mortality concerning several severe disorders, i.e. cancer, diabetes, stroke, inflammation, stroke and cardiovascular risk. Vice versa different drugs used in the treatment of these disorders have a favourable effect in depressive states, e.g. statins, aspirine, NSAIDs, pioglitazone, celecoxib, peroxisome proliferator-activated receptor-gamma agonists and minocycline. In this review, actions of different antidepressant treatment strategies on cancer, stroke, diabetes and cardiovascular disorders are shown and the influence on the outcome of the disorders is differentially discussed. In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2017) conducted a review in Depression in the context of medical disorders. Pharmacological treatments (antidepressants, statins, NSAIDs) was evaluated. Antidepressants exert modulatory effects on severe medical disorders, while drugs such as statins and NSAIDs demonstrate favorable effects in depressive states.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: